Therapeutic role of imatinib mesylate in chronic myeloid leukemia.

Authors

  • Asma Khan HITEC Institute of Medical Sciences, Taxila.
  • Zabiullah Rawalpindi Medical University, Rawalpindi.
  • Faizan Rasheed Rawalpindi Medical University, Rawalpindi.
  • Zarafshan Bader Fauji Foundation Medical College.
  • Imrana Aamir Fazaia Medical College, Islamabad.

DOI:

https://doi.org/10.29309/TPMJ/2025.32.10.9812

Keywords:

Chronic Myeloid Leukemia, HPLC, Imatinib

Abstract

Objective: To evaluate the impact of demographic (age, gender) and genetic (rs683369) factors on the therapeutic response to Imatinib Mesylate. Study Design: Prospective, Non-interventional Observational Study. Setting: Islamic International Medical College and Holy Family Hospital, with Genetic Testing at KRL Hospital, Islamabad. Period: January 2019 to December 2022. Methods: Included 106 CML patients aged 18–75 years, receiving 400 mg/day of Imatinib Mesylate. Response was assessed after three months based on hematological markers and Philadelphia chromosome presence. rs683369 genotyping was performed using PCR-RFLP, and plasma Imatinib levels were measured after one month. Statistical analysis included chi-square tests and binary logistic regression using SPSS. Period: January 2019 to December 2022. Results: Gender was significantly associated with treatment response, with females showing a higher response rate (p < 0.001). Older patients (≥51 years) exhibited higher plasma drug levels. The CC genotype of rs683369 was significantly associated with a favorable response compared to CG and GG genotypes (p = 0.04). Conclusion: Age, gender, and rs683369 genotype significantly influence Imatinib response in Pakistani CML patients. These findings support the application of pharmacogenetics in developing personalized treatment strategies.

Author Biographies

Asma Khan, HITEC Institute of Medical Sciences, Taxila.

MBBS, M.Phil, Ph.D, Associate Professor Pharmacology & Therapeutics, 

Zabiullah, Rawalpindi Medical University, Rawalpindi.

MBBS, Research Associate, 

Faizan Rasheed, Rawalpindi Medical University, Rawalpindi.

MBBS, Research Associate, 

Zarafshan Bader, Fauji Foundation Medical College.

MBBS, M.Phil, Associate Professor Pharmacology & Therapeutics, 

Imrana Aamir, Fazaia Medical College, Islamabad.

MBBS, M.Phil, Professor Pharmacology & Therapeutics, 

Downloads

Published

2025-10-02

Issue

Section

Origianl Article